🧬 You Don’t See the Path, You Take the Next Step | Sujal Patel (Part 4/4)

What It Covers

Sujal Patel, co-founder and CEO of Nautilus Biotechnology, explains why proteomics remains scientifically underserved despite 95% of FDA-approved drugs targeting proteins, how Nautilus built four distinct technical pillars over nine years and ~$500M to analyze billions of protein molecules simultaneously, and what commercialization looks like starting in neurology.

Key Questions Answered

• •Proteomics market gap: Current mass spectrometry workflows physically fragment proteins into peptides, then infer original sequences by weight — producing irreproducible data. Since 95% of FDA-approved drugs target proteins, this reproducibility failure directly limits drug discovery and AI-driven diagnostics. Researchers seeking reliable protein biomarkers should evaluate platforms that analyze intact molecules rather than inferred fragments.
• •Iterative multi-probe identification: Nautilus's platform spatially separates billions of molecules onto a chip at ~1-micron spacing, then repeatedly exposes each molecule to different antibodies, stacking hundreds of binding-event data points per molecule — similar to GPS triangulation across multiple signals. This eliminates the need for one dedicated antibody per protein variant, sidestepping a library of millions.
• •Four-pillar hard-tech timeline: Building Nautilus required four parallel development tracks — semiconductor flow-cell fabrication, a novel antibody probe library, a new iterative binding assay, and ML-based identification algorithms — each taking years independently. Founders tackling multi-pillar deep tech should budget roughly 10 years and $500M even with a clear technical roadmap, and expect each milestone to take longer than projected.
• •Managing PhD scientists in startups: PhD researchers default to risk-averse, completion-before-reporting work styles that conflict with startup iteration speed. Patel addressed this by separating the problem: learning the science himself via YouTube lectures at 2x speed and daily "dumb questions" sessions with co-founder Parag Malik, then developing separate management frameworks for scientific staff distinct from software engineering norms.
• •Commercialization entry strategy: Nautilus targets three buyer archetypes — existing mass spec users, genomics researchers expanding into proteomics, and biologists focused purely on answers. Initial instrument packages are priced at ~$1M, with annual consumable spend potentially reaching $1M per instrument at scale. Early access is concentrated in neurology, specifically tau proteoform research with partners including the Buck Institute and Allen Institute for Brain Sciences.